The CancerConnect Lung Cancer Newsletter

TraceyS

Stay Current With Lung Cancer Treatment Advances & Connect with Others

CancerConnect publishes daily cancer news, original articles and "tips" on the management of Lung Cancer. These are available in our monthly Lung Cancer newsletter.

Stay Current - Connect With Other Lung Cancer Patients

Join The CancerConnect Community: Connect with others and receive regular updates

Sign up for the Lung Cancer Newsletter Here

Comments

Lung Cancer

FEATURED

COMMUNITY

Treatment & Management of Non Small Cell Lung Cancer

Understand the role of precision cancer medicine, surgery, chemotherapy and radiation in the management of NSCLC.

Cancer Connect

Overview of Lung Cancer

Lung Cancer; Risk factors, diagnostic evaluation, staging and treatment planning.

Cancer Connect

Precision Cancer Medicines & Immunotherapy for Lung Cancer

Keep up with the growing number of precision medicines targeting specific mutations in lung cancer.

MedMaven

Treatment of Stage I - IIIA Non-Small Cell Lung Cancer

Update on the management of early stage NSCLC with precision medicines - immunotherapy.

Cancer Connect

Tecentriq® Improves Survival in Newly Diagnosed and Recurrent NSCLC

The Tecentriq® Checkpoint Inhibitor Improves NSCLC survival when used alone and when combined with Avastin-chemotherapy.

Cancer Connect

In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR + Lung Cancer

TKI therapy for EGFR + NSCLC continue to evolve and improve survival. Tagrisso resistance mutation recently identified.

Cancer Connect

Zepzelca (Lurbinectedin) Active in Treatment of Small Cell Lung Cancer

The new drug Lurbinectedin appears active in the treatment of small cell lung cancer and was FDA approved in June 2020.

MedMaven

How Should Oligometastatic NSCLC be Treated?

Local ablative treatment combined with immunotherapy improves long term survival in oligometastatic NSCLC.

MedMaven

Tumor Mutational Burden Predicts for Response to Immuotherapy in NSCLC

Research suggests that tumor mutational burden assessment can help predict response to immunotherapy in NSCLC.

MedMaven

Sotorasib (AMG 510) A New Precision Cancer Medicine to Finally Target KRAS NSCLC

KRAS a major driver of lung and other cancers gets FDA Breakthrough Status Designation for KRAS G12C mutated NSCLC.

MedMaven